戻る Agenda
ACTIV: A Public-Private Partnership to Speed COVID-19 Therapies and Vaccines
Session Chair(s)
Robin M. Weinick, PHD
SVP/Managing Director Americas and Global Program Officer
DIA, United States
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership brings together senior leaders from the Foundation for the National Institutes of Health (FNIH), NIH, FDA, BARDA, CDC, EMA, and the pharmaceutical industry to advance vaccines and therapies for COVID-19. The goal for the ACTIV partnership is to develop a framework to prioritize vaccine and therapeutic candidates in development and connect clinical trial networks to test new and repurposed candidates. In this session, representatives from the NIH, BARDA, EMA, FDA, and industry will provide an overview of the activities that are being undertaken by the ACTIV partnership.
Learning Objective : Describe how government and industry are collaborating to develop an international strategy for a coordinated research response to the COVID-19 pandemic; Discuss how a collaborative framework will prioritize vaccine and drug candidates, streamline clinical trials, coordinate regulatory processes, and/or leverage assets.
Speaker(s)
FDA Update
Peter W. Marks, MD, PHD
DIA Fellow, United States
Industry Update
Thomas Hudson, MD
AbbVie, United States
Senior Vice President, Research and Development, and Chief Scientific Officer
FNIH Update
David Wholley, MA
Foundation for National Institutes of Health (FNIH), United States
Senior Vice President of Research Partnerships